Basic Information
| LncRNA/CircRNA Name | TUC338 |
| Synonyms | NA |
| Region | GRCh38_12:53464468-53465057 |
| Ensemble | ENSG00000282977 |
| Refseq | NR_109828 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR etc. |
| Sample | bladder cancer patients blood , HT-1376 and HT-1197 bladder cancer cell lines (ATCC) |
| Expression Pattern | up-regulated |
| Function Description | TUC338 was upregulated in early-stage bladder cancer patients and showed early diagnostic values. After surgical resection, plasma levels of TUC338 were significantly downregulated. miR-10b was also upregulated in bladder cancer patients.TUC338 and miR-10b were positive and significantly correlated in bladder cancer patients, but not in healthy controls.TUC338 and miR-10b overexpression significantly promoted bladder cancer cell invasion and migration.Therefore, TUC338 may promote bladder cancer at least partially by upregulating miR-10b. |
| Pubmed ID | 31162712 |
| Year | 2019 |
| Title | lncRNA TUC338 Is a Potential Diagnostic Biomarker for Bladder Cancer |
External Links
| Links for TUC338 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |